BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9242428)

  • 1. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation.
    Turner BC; Haffty BG; Narayanan L; Yuan J; Havre PA; Gumbs AA; Kaplan L; Burgaud JL; Carter D; Baserga R; Glazer PM
    Cancer Res; 1997 Aug; 57(15):3079-83. PubMed ID: 9242428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
    Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
    Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.
    Chernicky CL; Yi L; Tan H; Gan SU; Ilan J
    Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer.
    Webster NJ; Resnik JL; Reichart DB; Strauss B; Haas M; Seely BL
    Cancer Res; 1996 Jun; 56(12):2781-8. PubMed ID: 8665514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines.
    Lee CT; Wu S; Gabrilovich D; Chen H; Nadaf-Rahrov S; Ciernik IF; Carbone DP
    Cancer Res; 1996 Jul; 56(13):3038-41. PubMed ID: 8674059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors alpha and beta.
    Koda M; Sulkowski S; Garofalo C; Kanczuga-Koda L; Sulkowska M; Surmacz E
    Horm Metab Res; 2003; 35(11-12):794-801. PubMed ID: 14710360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.
    Maor S; Yosepovich A; Papa MZ; Yarden RI; Mayer D; Friedman E; Werner H
    Cancer Lett; 2007 Nov; 257(2):236-43. PubMed ID: 17766039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of insulin-like growth factor-I receptor, estrogen receptor alpha, Bcl-2 and Bax proteins in human breast cancer.
    Koda M; Przystupa W; Jarzabek K; Wincewicz A; Kanczuga-Koda L; Tomaszewski J; Sulkowska M; Wolczynski S; Sulkowski S
    Oncol Rep; 2005 Jul; 14(1):93-8. PubMed ID: 15944774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1.
    Maor S; Mayer D; Yarden RI; Lee AV; Sarfstein R; Werner H; Papa MZ
    J Endocrinol; 2006 Dec; 191(3):605-12. PubMed ID: 17170218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas.
    Weber MM; Fottner C; Liu SB; Jung MC; Engelhardt D; Baretton GB
    Cancer; 2002 Nov; 95(10):2086-95. PubMed ID: 12412161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of IGF-I receptor in HeLa cells enhances in vivo radioresponse.
    Kaneko H; Yu D; Miura M
    Biochem Biophys Res Commun; 2007 Nov; 363(4):937-41. PubMed ID: 17920037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling.
    Pandini G; Vigneri R; Costantino A; Frasca F; Ippolito A; Fujita-Yamaguchi Y; Siddle K; Goldfine ID; Belfiore A
    Clin Cancer Res; 1999 Jul; 5(7):1935-44. PubMed ID: 10430101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma.
    Peiró G; Benlloch S; Sánchez-Tejada L; Adrover E; Lerma E; Peiró FM; Sánchez-Payá J; Aranda FI
    Breast Cancer Res Treat; 2009 Sep; 117(2):433-41. PubMed ID: 18683043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.